Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
SCRI Development Innovations, LLC
Study ID
NCT00193505
Phase
PHASE2
Status
Completed

Conditions

  • Non-Hodgkins Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ifosfamide — DRUG
  • Carboplatin — DRUG
  • Etoposide — DRUG
  • Rituximab — DRUG
  • 90Y Zevalin — DRUG

Study Details

In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.

Key Dates

Start date
Oct 31, 2003
Status verified
May 2011
Primary completion
Aug 31, 2005
Completion
Aug 31, 2005

Study Design

Enrollment
40 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

complete response rate

Locations (1)

FacilityCityStateZIPSite coordinators
Tennessee Oncology, PLLCNashvilleTennessee37023-

Find similar trials in Nashville, TN

By research site
Tennessee Oncology, PLLC· Nashville, TN

Related Studies